AXDX - Accelerate Diagnostics, Inc Company Long-Term Debts

Graphic logo of Accelerate Diagnostics Inc (AXDX)

Accelerate Diagnostics (AXDX) is integrating automation into diagnostics, eliminating routine manual labor for laboratories. The brand is highly valued by intensive care specialists for its lightning-fast sepsis detection. The market price action of the company's securities on GURU.Markets at the value of 0.00 reflects current trends. Patent-protected rapid tests create a technological barrier, although slow commercialization is temporarily constraining the potential of this competitive advantage.

AXDX Accelerate Diagnostics: Company Long-Term Debts in the range 07/04/2022 - 05/24/2025

Financial and market metric breakdowns for Accelerate Diagnostics, Inc (AXDX)

- price and consensus price forecast:
Share Price acceleratediagnostics.com|AXDX - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Accelerate Diagnostics|AXDX - Total Company Value
- book capitalization data:
Equity per Share Accelerate Diagnostics|AXDX - Book Capitalization|Market Capitalization to Book Value Ratio acceleratediagnostics.com|AXDX - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Accelerate Diagnostics|AXDX - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Accelerate Diagnostics Inc|AXDX - Company Debts|Debts to Net Assets Accelerate Diagnostics|AXDX - Company Long-Term Debts|Short-Term Debt Volume Accelerate Diagnostics
General company analysis:AXDX (acceleratediagnostics.com)
Mass-produced product of Accelerate Diagnostics, Inc.

The specifics of developing rapid diagnostic systems at Accelerate Diagnostics (AXDX) directly impact the size of the firm's long-term borrowings. This indicator captures the total credit obligations with a maturity of more than one year. The metric measures the long-term debt load, allowing for an assessment of the stability of the liability structure. For a loss-making business, an increase in this figure signals a search for external financing for survival. A stable trend confirms management's ability to service debt amidst fierce competition.

Competing companies

Company Long-Term Indebtedness agilent.com A|Quest Diagnostics Incorporated - Company Long-Term Debts|ILMN: Company Long-Term Debts|Company Long-Term Debt Cologuard|Revvity Corp (RVTY) - Company Long-Term Indebtedness|BIO (Bio-Rad Laboratories) - Company Long-Term Debts|Company Long-Term Debts NNNN|Company Long-Term Debt Sotera Health (SHC)|Company Long-Term Debt Quidel Corporation QDEL|OPK: Company Long-Term Liabilities|CareDx - Long-Term Debt|Company Long-Term Debt MRVI (Maravai LifeSciences)|FLGT - Long-Term Debt Volume|Standard BioTools - Company Long-Term Debts|CTKB (Cytek Biosciences Inc) - Long-Term Debt Volume|OSUR: Company Long-Term Debt|Long-Term Debt Volume Exagen Diagnostics|Company Long-Term Debts MDXH|Company Long-Term Debts luciddx.com (LUCD)|Prenetics - Company Long-Term Debts|Company Long-Term Liabilities Insight Molecular Diagnostics, Inc. IMDX|TRIB: Company Long-Term Debts|PRPH - Company Long-Term Liabilities|Company Long-Term Debts AIMD|CODX (codiagnostics.com) - Long-Term Debt|Company Long-Term Debt HeartSciences|Company Long-Term Debt Biomerica Inc.|Cardio Diagnostics - Company Long-Term Debts|Long-Term Debt VRAX (Virax Biolabs Corp)|Company Long-Term Debt Bluejay Diagnostics|Company Long-Term Loans and Borrowings aspirawh.com AWH|CENTOGENE - Company Long-Term Debts|Enzo Biochem, Inc. (ENZ) - Company Long-Term Debts|FRES - Company Long-Term Liabilities|Genetic Technologies Limited (GENE) - Amount of Long-Term Liabilities|Company Long-Term Debts ME (23andMe Holding Co.)|Long-Term Debt psychemedics.com (PMD)